Patents Examined by Chun Dahle
-
Patent number: 9051373Abstract: The present invention relates to a variant Fc region comprising an amino acid substitution at position 238 of the Fc region as compared to a human parent Fc region, wherein the variant Fc region comprises a 238D substitution, wherein the variant Fc region binds Fc?RIIb with increased binding affinity compared to a human parent Fc region.Type: GrantFiled: February 11, 2013Date of Patent: June 9, 2015Assignee: Xencor, Inc.Inventors: Gregory Alan Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
-
Patent number: 9045551Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases characterized by aberrant DLL4 and/or VEGF expression or activity.Type: GrantFiled: June 11, 2014Date of Patent: June 2, 2015Assignee: AbbVie Inc.Inventors: Jijie Gu, Dominic J. Ambrosi, Susan E. Lappe, Yingchun Li, Jonathan A. Hickson, Deanna L. Haasch, Supriya Gupta, Ravi Chari, Camellia Zamiri, Louie Naumovski, Xianhua Cao
-
Patent number: 9046513Abstract: Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.Type: GrantFiled: August 25, 2011Date of Patent: June 2, 2015Assignee: AbbVie Inc.Inventors: Tariq Ghayur, Jochen G. Salfeld, Michael J. McPherson
-
Patent number: 9040041Abstract: The present invention relates to Fc variants with optimized Fc receptor binding properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized Fc receptor binding properties, and methods for using Fc variants with optimized Fc receptor binding properties.Type: GrantFiled: June 4, 2010Date of Patent: May 26, 2015Assignee: Xencor, Inc.Inventors: John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, John O. Richards, Gregory L. Moore, David F. Carmichael
-
Patent number: 9040666Abstract: The present application relates to antigen-binding proteins that are capable of binding to mammalian IgG. The frame-work regions of the antigen-binding proteins of the application preferably correspond to those of antibodies naturally that are devoid of light chains as may e.g. be found in camelids. The application further relates to nucleic acids that encode such antigen-binding proteins, to immunoadsorbent materials that comprise such proteins, to the uses of such immunoadsorbent materials for the purification of mammalian IgG antibodies and for therapeutic apheresis.Type: GrantFiled: July 8, 2008Date of Patent: May 26, 2015Assignee: BAC IP B.V.Inventors: Wilhelmus Josephus Johanna Hermans, Sandra Bezemer, Yvonne Mathalie Mijnsbergen
-
Patent number: 9035026Abstract: The present invention relates to binding molecules that specifically bind to the human Fc gamma receptor expressed on the surface of natural killer (NK) cells and macrophages (i.e. Fc?RIIIA), and in particular binding molecules that specifically bind the A form Fc?RIII but do not bind to the B form of Fc?RIII, as well as to the use of such binding molecules in the diagnosis and treatment of disease. The invention further extends to polynucleotides encoding such binding molecules, host cells comprising such polynucleotides and methods of producing binding molecules of the invention using such host cells.Type: GrantFiled: May 26, 2006Date of Patent: May 19, 2015Assignee: Affimed GMBHInventors: Karin Hoffmann, Sergey Kipriyanov, Stefan Knackmuss, Fabrice Le Gall, Melvyn Little, Uwe Reusch
-
Patent number: 9029508Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: GrantFiled: April 28, 2009Date of Patent: May 12, 2015Assignee: AbbVie Inc.Inventors: Tariq Ghayur, Susan E. Morgan-Lappe, Edward B. Reilly, Gillian A. Kingsbury, Andrew Phillips, Jieyi Wang, Randy L. Bell, Suzanne M. Norvell, Yingchun Li, Junjian Liu, Hua Ying
-
Patent number: 9028815Abstract: The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds Fc?RIIIA and/or Fc?RIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by Fc?R is desired, e.g., cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.Type: GrantFiled: July 13, 2011Date of Patent: May 12, 2015Assignee: MacroGenics, Inc.Inventors: Jeffrey Stavenhagen, Sujata Vijh, Christopher Rankin, Sergey Gorlatov, Ling Huang
-
Patent number: 9023997Abstract: Disclosed herein are antibodies and ILT5-binding fragments thereof that specifically bind to ILT5, e.g., human ILT5 (hILT5), and pharmaceutical compositions comprising such ILT5-binding antibodies and ILT5-binding fragments thereof.Type: GrantFiled: January 20, 2011Date of Patent: May 5, 2015Assignee: Merck Sharp & Dohme Corp.Inventors: Irina Apostolou, Paul Ponath, Joe Ponte, Michael Rosenzweig
-
Patent number: 9018245Abstract: The purpose of the present invention is to elucidate a relationship between deregulation of signaling by CD22 and a rapid response of B cells by IgG-BCR and the like, and to provide a method capable of inducing a rapid immune response and defending against infection instead of vaccine. The present invention relates to a method for promoting an immune response causing such a strong proliferation of clones and production of a large amount of antibody-producing cells as those seen in the memory immune response even in the naive B cells expressing IgM-BCR and IgD-BCR by inhibiting the CD22 function in B cells; and to a method for screening a substance capable of promoting the immune response based on a change in the CD22 function in B cells.Type: GrantFiled: December 21, 2007Date of Patent: April 28, 2015Assignee: Japan Science and TechnologyInventors: Takeshi Tsubata, Taishi Onodera
-
Patent number: 8987418Abstract: Engineered multivalent and multispecific binding proteins that bind IL-1? and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.Type: GrantFiled: July 3, 2014Date of Patent: March 24, 2015Assignee: AbbVie Inc.Inventors: Tariq Ghayur, JiJie Gu, Maria Harris, Carrie Goodreau, Sonal Saluja
-
Patent number: 8969526Abstract: The invention relates to engineered polypeptides comprising Fc variants and their uses. More specifically, Fc variants are described exhibiting reduced effector function. These variants cause a benefit for a patient suffering from a disease which could be treated with an antibody for which it is desirable to reduce the effector function elicited by antibodies.Type: GrantFiled: March 27, 2012Date of Patent: March 3, 2015Assignee: Roche Glycart AGInventors: Monika Baehner, Stefan Jenewein, Manfred Kubbies, Ekkehard Moessner, Tilman Schlothauer
-
Patent number: 8968730Abstract: The present invention relates to antibodies or fragments thereof that specifically bind the extracellular domain of Fc?RIIB, particularly human Fc?RIIB, and block the Fc binding site of human Fc?RIIB. The invention provides methods of treating cancer and/or regulating immune complex-mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention.Type: GrantFiled: July 3, 2008Date of Patent: March 3, 2015Assignee: MacroGenics Inc.Inventors: Scott Koenig, Maria Concetta Veri, Nadine Tuaillon
-
Patent number: 8957195Abstract: Anti-CD19 B4 antibodies with modified variable regions are disclosed. The modified anti-CD19 variable region polypeptides have alterations to one or more framework regions or complementarity determining regions of the heavy chain variable region or light chain variable region, thereby to reduce a T-cell response.Type: GrantFiled: March 21, 2014Date of Patent: February 17, 2015Assignee: Merck Patent GmbHInventors: Michael Super, Jonathan Davis, Pascal André Stein
-
Patent number: 8952132Abstract: Methods and compositions involving polypeptides having an aglycosylated antibody Fc domain. In certain embodiments, polypeptides have an aglycosylated Fc domain that contains one or more substitutions compared to a native Fc domain. Additionally, some embodiments involve an Fc domain that is binds some Fc receptors but not others. For example, polypeptides are provided with an aglycosylated Fc domain that selectively binds Fc?RIIa, but that is significantly reduced for binding to the highly homologous Fc?RIIb receptors. Furthermore, methods and compositions are provided for promoting antibody-dependent cell-mediated toxicity (ADCC) using a polypeptide having a modified aglycosylated Fc domain and a second non-Fc binding domain, which can be an antigen binding region of an antibody or a non-antigen binding region. Some embodiments concern antibodies with such polypeptides, which may have the same or different non-Fc binding domain.Type: GrantFiled: February 6, 2012Date of Patent: February 10, 2015Assignee: Research Development FoundationInventors: George Georgiou, Sang Taek Jung, William Kelton, Tae Hyun Kang
-
Patent number: 8951517Abstract: The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds Fc?RIIIA and/or Fc?RIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by Fc?R is desired, e.g., cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.Type: GrantFiled: March 18, 2013Date of Patent: February 10, 2015Assignee: MacroGenics, Inc.Inventors: Jeffrey Stavenhagen, Sujata Vijh, Christopher Rankin, Sergey Gorlatov, Ling Huang
-
Patent number: 8946387Abstract: The present invention relates to antibodies or fragments thereof that specifically bind Fc?RIIB, particularly human Fc?RIIB, more particularly the extracellular domain of Fc?RIIB with greater affinity than said antibodies or fragments thereof bind Fc?RIIA, particularly human Fc?RIIA, and block the Fc binding site of Fc?RIIB. The present invention also encompasses the use of an anti-Fc?RIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The present invention also encompasses the use of an anti-Fc?RIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies.Type: GrantFiled: August 5, 2008Date of Patent: February 3, 2015Assignee: MacroGenics, Inc.Inventors: Scott Koenig, Maria Concetta Veri, Nadine Tuaillon, Ezio Bonvini
-
Patent number: 8945546Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.Type: GrantFiled: May 23, 2012Date of Patent: February 3, 2015Assignee: Medarex, L.L.C.Inventors: Shrikant Deshpande, Haichun Huang, Mohan Srinivasan, Josephine M. Cardarelli, Changyu Wang, David Passmore, Vangipuram Rangan, Thomas E. Lane, Hans S. Keirstead, Michael T. Liu
-
Patent number: 8946385Abstract: An objective of the present invention is to provide chimeric receptors containing a mouse Fc? receptor extracellular domain and a human Fc? receptor transmembrane domain, or chimeric receptors containing a mouse Fc? receptor extracellular domain and a human ? chain transmembrane domain. Another objective of the present invention is to provide methods for measuring the ADCC activity of mouse antibodies and methods of screening for mouse antibodies having ADCC activity, using the chimeric receptors. To accomplish the above-mentioned objectives, the present inventors produced chimeric molecules by fusing the extracellular domain of mouse Fc?R3 or mouse Fc?R4 with the transmembrane domain/intracellular domain of human ? chain or human Fc?R3, and expressed the chimeric molecules in human NK92 cells.Type: GrantFiled: January 30, 2008Date of Patent: February 3, 2015Assignee: Chugai Seiyaku Kabushiki KaishaInventor: Shigeto Kawai
-
Patent number: 8937158Abstract: The present invention relates to Fc variants having increased affinity for Fc?RIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.Type: GrantFiled: August 20, 2007Date of Patent: January 20, 2015Assignee: Xencor, Inc.Inventors: Gregory Alan Lazar, Wei Dang, John R. Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes